Markets

Teva (TEVA) Beats on Q2 Earnings & Revenues

Highs and Lows Stock Data

Israel-based Teva Pharmaceutical Industries LimitedTEVA is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Teva's main branded products include Copaxone (multiple sclerosis) and Azilect (Parkinson's disease). Besides this, Teva's branded product portfolio consists of respiratory products like ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma.

Moreover, the company has several candidates in its pipeline. Earlier this week, Teva completed its acquisition of Allergan's generics business (Actavis Generics). The company also announced a deal to acquire Allergan's Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S., for $500 million. The Anda deal is slated to close in the second half of the year.

Teva's earnings track record has been good with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 4.56%.

Currently, TEVA has a Zacks Rank #2 (Buy), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings : TEVA's second quarter earnings came in at $1.25 per share, beating consensus estimates of $1.18.

Revenues : Teva posted revenues of $5 billion, surpassing consensus estimates of $4.8 billion.

Key Stats : Currency fluctuations cut second quarter revenues by about $141 million. Lead branded product, Copaxone, posted worldwide sales of $1.1 billion, up 8%. Meanwhile, generic revenues declined during the quarter.

2016 Outlook : The company expects revenues of $22.0-22.5 billion and earnings of $5.20-5.40 per share in 2016. The Zacks Consensus Estimate for 2016 revenue and earnings are $22.29 billion and $5.16 per share and, respectively.

TEVA PHARM ADR Price

TEVA PHARM ADR Price | TEVA PHARM ADR Quote

Check back later for our full write up on this TEVA earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TEVA

Other Topics

Earnings Investing Stocks

Latest Markets Videos